Emergent Biosolutions
EBS
EBS
297 hedge funds and large institutions have $2.53B invested in Emergent Biosolutions in 2018 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 106 increasing their positions, 105 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.34% more ownership
Funds ownership: 84.83% → 85.16% (+0.34%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less capital invested
Capital invested by funds: $2.79B → $2.53B (-$260M)
Holders
297
Holding in Top 10
4
Calls
$3.06M
Puts
$1.1M
Top Buyers
| 1 | +$57.5M | |
| 2 | +$19M | |
| 3 | +$18.2M | |
| 4 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
+$15.6M |
| 5 |
FA
Friess Associates
Greenville,
Delaware
|
+$15.2M |
Top Sellers
| 1 | -$19.8M | |
| 2 | -$18.2M | |
| 3 | -$18M | |
| 4 |
Renaissance Technologies
New York
|
-$16.3M |
| 5 |
Goldman Sachs
New York
|
-$13.8M |